The Science is Moving Fast
Alzheimer's research has produced more significant findings in the last five years than the previous two decades. These summaries cover the most important developments — new treatments, blood biomarkers, digital detection methods — and what they mean for people managing their cognitive health today.
40Hz Gamma Stimulation and Alzheimer's: What the Research Shows
MIT researchers discovered that flickering light and sound at 40 cycles per second reduces amyloid plaques in mice. Human trials are underway, but the science is still early.
Lecanemab (Leqembi): The First Drug to Slow Alzheimer's Decline
The CLARITY AD trial showed a 27% slowing of clinical decline in early Alzheimer's disease — a genuine clinical milestone, and a treatment with important limitations.
Donanemab (Kisunla): Eli Lilly's Alzheimer's Treatment and What Sets It Apart
The TRAILBLAZER-ALZ 2 trial showed donanemab slowing early-stage Alzheimer's decline by up to 35%, with the unique possibility of stopping treatment once amyloid is cleared.
Blood Tests for Alzheimer's: How Plasma Biomarkers Are Changing Early Detection
Plasma phosphorylated tau-217 and related tests now achieve diagnostic accuracy that rivals PET scanning — and could move early Alzheimer's detection into primary care.
Retinal Scans and Cognitive Decline: The Eye as a Window to the Brain
Amyloid deposits have been identified in the retina before they are detectable in the brain. Researchers are investigating whether a simple eye scan could become a non-invasive cognitive health screening tool.
The Gut Microbiome and Brain Health: What the Emerging Evidence Shows
The gut-brain axis — the communication highway between intestinal bacteria and the brain — is increasingly recognized as a factor in cognitive aging. The science is early but biologically compelling.
Digital Biomarkers for Cognitive Health: Typing, Gait, and Voice as Early Signals
Researchers are using everyday digital data — keyboard typing patterns, smartphone interactions, and gait sensor data — to detect subtle cognitive changes earlier than clinical assessments can.
AI and Dementia Detection: What Machine Learning Can and Cannot Do
Artificial intelligence applied to speech, drawing tests, retinal images, and brain scans is achieving near-clinical accuracy in some cognitive assessment domains. Here is what the evidence shows.
Sleep and Amyloid Clearance: The Glymphatic System and Alzheimer's Risk
During deep sleep, the brain's glymphatic system clears amyloid-beta and other waste products. Sleep disruption appears to accelerate amyloid accumulation — a strong mechanistic link to Alzheimer's risk.
You do not have to wait for a breakthrough
The treatments arriving now work best when caught early. The most actionable thing you can do today is establish a cognitive baseline — so you have objective data when the time comes to use it.
Free to start. No account required. Not a diagnostic tool.